Bristol-Myers Squibb - AI Stock Analysis

Analysis generated October 25, 2025

Bristol Myers Squibb (BMY) is a global biopharmaceutical company that is dedicated to discovering, developing, and delivering innovative medicines to patients with serious diseases. The company operates in a highly competitive pharmaceutical industry, with a robust portfolio of treatments in areas such as oncology, immunology, cardiovascular, and fibrosis.

Fundamental Analysis

In the most recent quarter, Bristol Myers Squibb reported revenue of $12.3 billion. This figure represents a 9.53% increase compared to the previous quarter, demonstrating positive short-term growth momentum. Year over year, revenue has increased by 0.56%, indicating stable long-term growth.

However, the company’s net income for the last quarter was $1.31 billion, signifying a decrease of 46.66% compared to the prior quarter. This substantial decline highlights a potential area of concern for investors. When compared to the same quarter the previous year, net income has decreased by 22.02%, which may signal underlying challenges in profitability.

The EBITDA for the last quarter stood at $3.29 billion, a decline of 26.58% from the preceding quarter and a decrease of 25.35% year over year. These decreases in EBITDA suggest that the company is facing operational inefficiencies or increased costs that are affecting its earnings before interest, tax, depreciation, and amortization.

The current Price-to-Earnings (P/E) ratio of 17.6 is within a normal range for the industry, suggesting that the stock is neither significantly overvalued nor undervalued based on its earnings.

Technical Analysis

Today’s stock price for Bristol Myers Squibb is $43.83, marking a 2.33% increase compared to a month ago. This indicates a short-term positive trend. However, compared to a year ago, the stock price has decreased by 11.37%, which could be concerning for long-term investors.

The stock is currently experiencing a bullish trend. The Simple Moving Average over 10 days (SMA10) stands at $43.83, slightly higher than the previous SMA10 of $43.81, suggesting a potential upward trend in price movement. The Relative Strength Index (RSI) is at 62.3, indicating neutral market conditions.

Alternative Data Analysis

Bristol Myers Squibb has 859 open job positions, according to data from popular job boards. The number of job postings has remained stable over the last few months, indicating consistent operational stability.

Employee sentiment, however, is relatively low, with only 41% of employees having a positive business outlook. This may reflect internal concerns or dissatisfaction that could impact future performance.

In terms of customer acquisition, the company has an estimated 960,000 visitors to their webpage, a 23% increase in the last few months. This bullish trend suggests a potential increase in customer interest and engagement.

On social media, Bristol Myers Squibb has 0 followers on their Instagram page with no significant change in follower count. On Twitter, the company has 150,000 followers, with no change in the last few months, indicating a stable but unchanging level of interest.

AltIndex’s AI score for Bristol Myers Squibb is 63, which signals a buy recommendation based on the aggregation of fundamental, technical, and alternative data analyses.

Conclusion

Based on the analysis, Bristol Myers Squibb demonstrates a mixed financial performance. While revenue growth is positive, significant declines in net income and EBITDA highlight operational and profitability concerns. The technical indicators present a bullish short-term trend but reveal a concerning long-term decline in stock price. Alternative data points to stable job postings and increased customer interest, but low employee sentiment raises questions.

Considering all these factors, Bristol Myers Squibb presents both opportunities and risks. Investors may find value in the company’s stable revenue growth and bullish short-term technicals, but should also weigh the concerns over profitability and long-term stock performance.

Disclaimer: This AI stock analysis, generated by an experimental AI tool, is for informational purposes only and not financial advice. Information is based on publicly available data and may not always be accurate or current.